Answers are grounded in this paper and cite their sources.
Highlights the need for transcatheter therapies for severe tricuspid regurgitation given the high mortality of isolated surgical intervention.
Tricuspid regurgitation (TR) represents the vast majority of tricuspid valve (TV) disease and affects more than 1.5 million patients in North America.1 The prognosis of untreated TR is generally poor, leading to frequent multiple hospital readmissions due to right heart failure, liver congestion, and kidney failure. However, isolated TV surgery remains rare and is associated with the highest perioperative mortality among all cardiac valve surgeries.2,3 Consequently, most patients with severe TR are relegated to receiving lifetime medical therapy.
No takes yet. Share an insight, caveat, or question.
Faroux et al. (2020) conducted an editorial in Tricuspid regurgitation. Transcatheter therapies vs. Medical therapy or isolated tricuspid valve surgery was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: